Maria Zanti

Ms. Maria Zanti

The Cyprus Institute of Neurology and Genetics
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Nature
Verified
Journal Article
Closed access
PDF file
SSSounak Sahu
Sounak Sahu
MGMelissa Galloux
Melissa Galloux
ESEileen Southon
Eileen Southon
DCDylan Caylor
Dylan Caylor
TSTeresa Sullivan
Teresa Sullivan
SSShyam K. Sharan
Shyam K. Sharan

26 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AOAnastasis Oulas
Anastasis Oulas
MZMaria Zanti
Maria Zanti
MTMarios Tomazou
Marios Tomazou
MZMargarita Zachariou
Margarita Zachariou
GMGeorge Minadakis
George Minadakis
GSGeorge Spyrou
George Spyrou
This study aims to highlight SARS-COV-2 mutations which are associated with increased or decreased viral virulence. We utilize genetic data from all strains available from GISAID and countries’ regional information, such as deaths and cases per million, as well as COVID-19-related public health austerity measure response times. Initial indications of selective advantage of specific mutations can be obtained from calculating their frequencies across viral strains. By applying modelling approaches, we provide additional information that is not evident from standard statistics or mutation frequencies alone. We therefore, propose a more precise way of selecting informative mutations. We highlight two interesting mutations found in genes N (P13L) and ORF3a (Q57H). The former appears to be significantly associated with decreased deaths and cases per million according to our models, while the latter shows an opposing association with decreased deaths and increased cases per million. Moreover, protein structure prediction tools show that the mutations infer conformational changes to the protein that significantly alter its structure when compared to the reference protein.

1 February 2018 in Human Gene Therapy Methods
Verified
Journal Article
Open access
CLConstantinos C. Loucari
Constantinos C. Loucari
PPPetros Patsali
Petros Patsali
TDThamar B. van Dijk
Thamar B. van Dijk
CSCoralea Stephanou
Coralea Stephanou
PPPanayiota Papasavva
Panayiota Papasavva
MKMarina Kleanthous
Marina Kleanthous
The β-hemoglobinopathies sickle cell anemia and β-thalassemia are the focus of many gene-therapy studies. A key disease parameter is the abundance of globin chains because it indicates the level of anemia, likely toxicity of excess or aberrant globins, and therapeutic potential of induced or exogenous β-like globins. Reversed-phase high-performance liquid chromatography (HPLC) allows versatile and inexpensive globin quantification, but commonly applied protocols suffer from long run times, high sample requirements, or inability to separate murine from human β-globin chains. The latter point is problematic for in vivo studies with gene-addition vectors in murine disease models and mouse/human chimeras. This study demonstrates HPLC-based measurements of globin expression (1) after differentiation of the commonly applied human umbilical cord blood–derived erythroid progenitor-2 cell line, (2) in erythroid progeny of CD34+ cells for the analysis of clustered regularly interspaced short palindromic repeats/Cas9-mediated disruption of the globin regulator BCL11A, and (3) of transgenic mice holding the human β-globin locus. At run times of 8 min for separation of murine and human β-globin chains as well as of human γ-globin chains, and with routine measurement of globin-chain ratios for 12 nL of blood (tested for down to 0.75 nL) or of 300,000 in vitro differentiated cells, the methods presented here and any variant-specific adaptations thereof will greatly facilitate evaluation of novel therapy applications for β-hemoglobinopathies.

25 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMaria Zanti
Maria Zanti
DODenise G. O’mAhony
Denise G. O’mAhony
MPMichael T. Parsons
Michael T. Parsons
LDLeila Dorling
Leila Dorling
JDJoe Dennis
Joe Dennis
KMKyriaki Michailidou
Kyriaki Michailidou
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyze germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 302,116 controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observe 11,207 BRCA1 and BRCA2 variants, with 6909 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control likelihood ratio (ccLR) evidence is highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.3% specificity for BRCA1 and 93.3% sensitivity and 86.6% specificity for BRCA2. This approach provides case-control evidence for 787 unclassified variants; these include 579 with strong or moderate benign evidence and 10 with strong pathogenic evidence for which ccLR evidence is sufficient to alter clinical classification.

13 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
KYKristia Yiangou
Kristia Yiangou
NMNasim Mavaddat
Nasim Mavaddat
JDJoe Dennis
Joe Dennis
MZMaria Zanti
Maria Zanti
QWQin Wang
Qin Wang
KMKyriaki Michailidou
Kyriaki Michailidou
The 313-variant polygenic risk score (PRS 313 ) provides a promising tool for breast cancer risk prediction. However, evaluation of the PRS 313 across different European populations which could influence risk estimation has not been performed. Here, we explored the distribution of PRS 313 across European populations using genotype data from 94,072 females without breast cancer, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 225,105 female participants from the UK Biobank. The mean PRS 313 differed markedly across European countries, being highest in south-eastern Europe and lowest in north-western Europe. Using the overall European PRS 313 distribution to categorise individuals leads to overestimation and underestimation of risk in some individuals from south-eastern and north-western countries, respectively. Adjustment for principal components explained most of the observed heterogeneity in mean PRS. Country-specific PRS distributions may be used to calibrate risk categories in individuals from different countries.

27 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MZMaria Zanti
Maria Zanti
Maria A. LoizidouMaria A. Loizidou
Maria A. Loizidou
KMKyriaki Michailidou
Kyriaki Michailidou
PPPanagiota Pirpa
Panagiota Pirpa
CMChristina Machattou
Christina Machattou
AHAndreas Hadjisavvas
Andreas Hadjisavvas
In Cyprus, approximately 9% of triple-negative (estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative) breast cancer (TNBC) patients are positive for germline pathogenic variants (PVs) in BRCA1/2. However, the contribution of other genes has not yet been determined. To this end, we aimed to investigate the prevalence of germline PVs in BRCA1/2-negative TNBC patients in Cyprus, unselected for family history of cancer or age of diagnosis. A comprehensive 94-cancer-gene panel was implemented for 163 germline DNA samples, extracted from the peripheral blood of TNBC patients. Identified variants of uncertain clinical significance were evaluated, using extensive in silico investigation. Eight PVs (4.9%) were identified in two high-penetrance TNBC susceptibility genes. Of these, seven occurred in PALB2 (87.5%) and one occurred in TP53 (12.5%). Interestingly, 50% of the patients carrying PVs were diagnosed over the age of 60 years. The frequency of non-BRCA PVs (4.9%) and especially PALB2 PVs (4.3%) in TNBC patients in Cyprus appears to be higher compared to other populations. Based on these results, we believe that PALB2 and TP53 along with BRCA1/2 genetic testing could be beneficial for a large proportion of TNBC patients in Cyprus, irrespective of their age of diagnosis.